Dr. Stacey Goodman, MD

NPI: 1639278062
Total Payments
$205.59
2024 Payments
$78.21
Companies
3
Transactions
4
Medicare Patients
109
Medicare Billing
$12,604

Payment Breakdown by Category

Food & Beverage$116.34 (56.6%)
Research$89.25 (43.4%)
Other$0.00 (0.0%)

Payments by Nature

Nature of Payment Amount Transactions Share
Food and Beverage $116.34 3 56.6%
Unspecified $89.25 1 43.4%

Payments by Type

General
$116.34
3 transactions
Research
$89.25
1 transactions

Top Paying Companies

Company Total Records Latest Year
Takeda Pharmaceuticals U.S.A., Inc. $89.25 1 $0 (2019)
Novo Nordisk Inc $78.21 1 $0 (2024)
Amgen Inc. $38.13 2 $0 (2018)

Payment History by Year

Year Amount Transactions Top Company
2024 $78.21 1 Novo Nordisk Inc ($78.21)
2019 $89.25 1 Takeda Pharmaceuticals U.S.A., Inc. ($89.25)
2018 $38.13 2 Amgen Inc. ($38.13)

All Payment Transactions

4 individual payment records from CMS Open Payments

Date Company Product Nature Form Amount Type
05/28/2024 Novo Nordisk Inc Food and Beverage In-kind items and services $78.21 General
03/22/2019 Takeda Pharmaceuticals U.S.A., Inc. Ninlaro (Drug) Cash or cash equivalent $89.25 Research
Study: Study of Dexamethasone Plus IXAZOMIB MLN9708 or Physicians Choice of Treatment in Relapsed or Refractory Systemic Light Chain AL Amyloidosis • Category: Oncology
08/02/2018 Amgen Inc. Neulasta (Biological), Vectibix, XGEVA Food and Beverage In-kind items and services $16.13 General
Category: Oncology
03/05/2018 Amgen Inc. Neulasta (Biological), Vectibix, XGEVA Food and Beverage In-kind items and services $22.00 General
Category: Oncology

Research Studies & Clinical Trials

Study Name Company Amount Records
Study of Dexamethasone Plus IXAZOMIB MLN9708 or Physicians Choice of Treatment in Relapsed or Refractory Systemic Light Chain AL Amyloidosis Takeda Pharmaceuticals U.S.A., Inc. $89.25 1

Medicare Billing by Year

Year Procedures Beneficiaries Services Submitted Medicare Paid
2021 1 36 56 $17,808 $3,486
2020 2 73 167 $53,019 $9,118
Total Patients
109
Total Services
223
Medicare Billing
$12,604
Procedure Codes
3

All Medicare Procedures & Services

3 procedure records from CMS Medicare Utilization

HCPCS Description Setting Year Patients Services Charges Medicare Paid Ratio
99214 Established patient outpatient visit, total time 30-39 minutes Facility 2021 36 56 $17,808 $3,486 19.6%
99214 Established patient office or other outpatient, visit typically 25 minutes Facility 2020 47 127 $37,626 $6,126 16.3%
99215 Established patient office or other outpatient, visit typically 40 minutes Facility 2020 26 40 $15,393 $2,992 19.4%

About Dr. Stacey Goodman, MD

Dr. Stacey Goodman, MD is a Hematology healthcare provider based in Nashville, Tennessee. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 09/22/2006. The National Provider Identifier (NPI) number assigned to this provider is 1639278062.

According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Stacey Goodman, MD has received a total of $205.59 in payments from pharmaceutical and medical device companies, with $78.21 received in 2024. These payments were reported across 4 transactions from 3 companies. The most common payment nature is "Food and Beverage" ($116.34).

As a Medicare-enrolled provider, Goodman has provided services to 109 Medicare beneficiaries, totaling 223 services with total Medicare billing of $12,604. Data is available for 2 years (2020–2021), covering 3 distinct procedure/service records.

Practice Information

  • Specialty Hematology
  • Location Nashville, TN
  • Active Since 09/22/2006
  • Last Updated 10/15/2020
  • Taxonomy Code 207RH0000X
  • Entity Type Individual
  • NPI Number 1639278062

Products in Payments

  • Ninlaro (Drug) $89.25
  • Neulasta (Biological) $38.13

Data Sources

Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.

Hematology Doctors in Nashville